Clinical Trial

Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

Study acronym: RASolute 302
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to standard(s) of care (SOC) treatment.
Protocol Amendment History 36 amendments
This ClinicalTrials.gov record has been amended 36 times since 2024-10-01; most recent amendment 2026-05-29.
Status change: Recruiting → Active, Not Recruiting 2025-12-05
Status change: Not Yet Recruiting → Recruiting 2024-10-02
Trial Details
NCT Number NCT06625320
Lead Sponsor Revolution Medicines, Inc.
Conditions Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma
Enrollment 500 participants
Start Date 2024-10-16
Primary Completion 2026-06 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2026-06-02